VASOCIDIN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOCIDIN is an ophthalmic solution approved in 1988 for eye-related indications. The exact mechanism of action and therapeutic target are not publicly detailed in available data, but the product is positioned as a small-molecule eye drop therapy. It remains a legacy product in Novartis's ophthalmology portfolio.
LOE Approaching
As LOE approaches, the brand team is likely focused on lifecycle management and operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VASOCIDIN offers exposure to lifecycle management and defensive commercial strategy in a mature ophthalmology franchise. Career growth on this product is limited; professionals should view it as a training ground for brand management fundamentals or a stepping stone to growth-stage products.
Brand ManagerField Sales Representative
Worked on VASOCIDIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.